Viridian Therapeutics, Inc.
VRDN
$23.01
-$0.17-0.71%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -127.12M | -104.90M | -120.36M | -34.60M | -100.74M |
| Total Depreciation and Amortization | 117.00K | 121.00K | -380.00K | 610.00K | 113.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 23.51M | 6.52M | 15.63M | 9.71M | 9.38M |
| Change in Net Operating Assets | -1.84M | -21.39M | 81.35M | -60.33M | 15.87M |
| Cash from Operations | -105.32M | -119.65M | -23.75M | -84.61M | -75.37M |
| Capital Expenditure | -1.31M | -23.00K | -240.00K | -127.00K | -42.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -229.85M | 77.28M | -339.18M | 126.20M | 75.76M |
| Cash from Investing | -231.16M | 77.26M | -339.42M | 126.08M | 75.72M |
| Total Debt Issued | 250.00M | -- | 28.88M | -- | -- |
| Total Debt Repaid | -54.70M | -- | -- | -- | -- |
| Issuance of Common Stock | 145.60M | 6.36M | 345.74M | 11.07M | 764.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -15.78M | -- | 31.30M | -209.00K | 0.00 |
| Cash from Financing | 325.12M | 6.36M | 405.91M | 10.86M | 764.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.36M | -36.04M | 42.74M | 52.32M | 1.11M |